Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy. Patients given sitagliptin in addition to insulin had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin. Led by Paolo Fiorina, MD, Ph.D., of Boston Children's Hospital, the study involved seven Italian hospitals during the first surge of COVID cases last spring.
[Source: medicalxpress.com] [ Comments ] [See why this is trending]